SGCG and Other metabolic disease: Pharmacological agents like the dynein‐antagonist LDC‐3/Dynarrestin, metformin, and sulforaphane, which modulate ER‐mitochondria contacts by regulating MAM‐tethering proteins, are currently undergoing preclinical and clinical trials for cancer and metabolic disorders.26, 78, 79, 80, 81, 82, 83